Grifols Management

Management criteria checks 2/4

Grifols' CEO is Nacho Abia Buenache, appointed in Apr 2024, has a tenure of less than a year. directly owns 0.014% of the company’s shares, worth MX$15.37M. The average tenure of the management team and the board of directors is 6.6 years and 6.8 years respectively.

Key information

Nacho Abia Buenache

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.01%
Management average tenure	6.6yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO

Nacho Abia Buenache (56 yo)

less than a year

Tenure

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Glanzmann	Executive Chairman	18.3yrs	€1.90m	0.029% MX$ 32.7m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	no data	0.014% MX$ 15.4m
Alfredo Guerra	CFO & VP	17.6yrs	no data	no data
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	no data	no data
Nuria Lapeña	VP of Corporate Treasury	no data	no data	no data
David Bell	Chief Corporate Development	21.6yrs	no data	0.0029% MX$ 3.3m
Maria Teresa-Rioné Llano	Chief Communications Officer	6.6yrs	no data	0.00078% MX$ 877.6k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	no data	no data
Vicente Blanquer Torre	Chief Quality Officer	31.6yrs	no data	0.0066% MX$ 7.4m
Sergio Adell	President of Commercial Tech Support	5.6yrs	no data	no data
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% MX$ 17.9m
Miguel Montblanch	President of Commercial Operations Support	12.6yrs	no data	no data

6.6yrs

Average Tenure

59.5yo

Average Age

Experienced Management: GRFP N's management team is seasoned and experienced (6.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Glanzmann	Executive Chairman	18.3yrs	€1.90m	0.029% MX$ 32.7m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	no data	0.014% MX$ 15.4m
Víctor Grifols Deu	Executive Director	8.3yrs	€1.04m	0.016% MX$ 17.9m
Juan Twose Roura	Member of the Advisory Committee	9.6yrs	€380.00k	no data
Raimon Grifols Roura	Vice-Chairman	9.3yrs	€1.04m	0.0060% MX$ 6.8m
Tomas Daga Gelabert	Independent External Director	24.3yrs	no data	0.045% MX$ 50.3m
Inigo Mardones	Independent Director	9.3yrs	€150.00k	no data
Albert Coma-Cros	Proprietary Director	less than a year	no data	0.0097% MX$ 10.9m
Enriqueta Font	Independent Director	5.3yrs	€125.00k	no data
Montserrat Abellana	Lead Independent Director	2.2yrs	€63.00k	no data
Susana Gonzalez Rodriguez	Independent Director	2.2yrs	€63.00k	no data
Anne-Catherine Berner	Independent Director	less than a year	no data	no data

6.8yrs

Average Tenure

60yo

Average Age

Experienced Board: GRFP N's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/08/13 17:42
End of Day Share Price	2024/05/16 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Grifols, S.A. is covered by 42 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Elena Fernández	Ahorro Corporación
Kamla Singh	AlphaValue
Guilherme Sampaio	Banco BPI, S.A.

Grifols Management

Management criteria checks 2/4

Key information

Recent management updates

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols Announces Executive Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Recent updates

Flat Footed Calls for Prompt Governance Overhaul at Grifols

Brookfield Capital Partners (Uk) Limited and Grifols family cancelled the acquisition of remaining stake in Grifols, S.A. (BME:GRF).

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols Announces Executive Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources